Foslevodopa

Last updated

Foslevodopa
Foslevodopa.svg
Identifiers
  • (2S)-2-Amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C9H12NO7P
Molar mass 277.169 g·mol−1
3D model (JSmol)
  • C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O
  • InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1
  • Key:YNDMEEULGSTYJT-LURJTMIESA-N

Foslevodopa is a medication which acts as a prodrug for levodopa, originally invented in the 1980s but not developed for medical use at that time. [1] It is approved for use in a subcutaneous infusion as a fixed-dose combination with foscarbidopa for the treatment of Parkinson's disease, under the brand name Vyalev. [2] [3]

References

  1. ↑ Agin PP, Sayre RM, Pawelek JM (1987). "Phosphorylated mixed isomers of L-dopa increase melanin content in skins of Skh-2 pigmented hairless mice". Pigment Cell Research. 1 (3): 137–142. doi:10.1111/j.1600-0749.1987.tb00404.x. PMID   3149738.
  2. ↑ Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR (August 2024). "Subcutaneous Levodopa: A New Engine for the Vintage Molecule". Neurology and Therapy. 13 (4): 1055–1068. doi:10.1007/s40120-024-00635-4. PMC   11263521 . PMID   38874708.
  3. ↑ Fung VS, Aldred J, Arroyo MP, Bergquist F, Boon AJ, Bouchard M, et al. (2024). "Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance". Clinical Parkinsonism & Related Disorders. 10 100239. doi:10.1016/j.prdoa.2024.100239. PMC   10900117 . PMID   38419617.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.